Anika Therapeutics | ANIK - Operating Expenses


Anika Therapeutics reported $133.9M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Abbott USD 9.31B 104M Mar/2026
Agenus USD -221.22M 241.03M Mar/2026
Agios Pharmaceuticals USD 130.77M 10.77M Mar/2026
Anika Therapeutics USD 133.9M 103.93M Mar/2026
Arrowhead Research USD 215M 8.23M Mar/2026
Enanta Pharmaceuticals USD 126.59M 346.51M Dec/2025
Halozyme Therapeutics USD 192.19M 18.88M Mar/2026
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Insmed USD 506.24M 7.31M Mar/2026
Integra LifeSciences USD 1.04B 673.49M Mar/2026
Intrexon USD 61.56M 26.1M Jun/2024
J&J USD 17.44B 1.53B Mar/2026
Karyopharm Therapeutics USD 51.92M 9.9M Dec/2025
Ligand Pharmaceuticals USD 34.35M 5.27M Mar/2026
MacroGenics USD 21.2M 32.13M Mar/2026
Merit Medical Systems USD 337.72M 2.02M Mar/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sanofi EUR 9.31B 1.2B Mar/2026
Smith & Nephew USD 2.52B 84M Dec/2025
Stryker USD 4.92B 284M Mar/2026
Veracyte USD 119.99M 3.99M Mar/2026
Xencor USD 82.38M 513K Mar/2026
Zimmer Biomet Holdings USD 1.69B 249.3M Mar/2026